Breaks Categories: News

WednesdayAug 26, 2020 11:46 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Engages Worldwide to Further Drive Berubicin’s Clinical Development

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced its engagement of Worldwide Clinical Trials as the contract research organization ("CRO") for its upcoming Berubicin clinical trials. Worldwide, which specializes in therapeutic areas where there remain unmet medical needs, is a midsize, global CRO that provides drug development services to biopharmaceutical companies in clinical trials. "Designing and operating trials in areas of high unmet medical need, such as glioblastoma, is a challenging and complex task for any company. We are excited…

Continue Reading

WednesdayAug 26, 2020 11:08 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Invited to Present at Prestigious LD 500 Virtual Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it joins the lineup of presenters at this year’s LD 500 Virtual Investor Conference. The annual LD Conference spotlights some of the most prominent companies in the micro-cap world, and also includes interviews and keynotes with small-cap leaders. GNPX chairman and CEO Rodney Varner will provde a company overview as well as updates on Genprex’s lead drug candidate, GPX-001, which recently received fast track designation from the U.S. Food and Drug Administration for use in combination with AstraZeneca's Tagrisso(R) for…

Continue Reading

ThursdayAug 20, 2020 11:48 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Lands Milestone Contract with Major Pharmaceutical Company

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its Soluble Biotech division has finalized its first major contract since being acquired by POAI earlier this year. The contract calls for a project involving protein expression followed by solubility studies, both areas of expertise for Soluble Biotech. The new POAI division provides soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” said former NASA…

Continue Reading

WednesdayAug 19, 2020 10:40 am

BioMedNewsBreaks – Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High

Shares of DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, reached a new 52-week high on Wednesday. In morning trading, the company’s shares reached a peak of $22.49 on volume of over 170,000, up from an opening price of $18.75. At time of publishing, shares of DRIO hover around $21.35, marking a PPS increase of roughly 13.87% on the day. About DarioHealth Corp. DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the…

Continue Reading

TuesdayAug 18, 2020 11:48 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Sale of 8 Skyline Medical STREAMWAY(R) Systems to Large University Hospital Organization

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal, has completed the sale of eight systems to a large university hospital organization in Virginia for a new surgical center. According to the update, the organization already has two STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 annual procedures. To view the full press release, visit http://ibn.fm/mzHmo About Predictive Oncology Inc. Predictive Oncology operates through…

Continue Reading

MondayAug 17, 2020 2:05 pm

BioMedNewsBreaks – Aegis Capital Corp. Initiates Coverage, Issues ‘Buy’ Rating on DarioHealth Corp. (NASDAQ: DRIO)

Aegis Capital Corp. has initiated coverage with a ‘Buy’ rating and price target of $25 on shares of DarioHealth’s (NASDAQ: DRIO) stock. DRIO is a pioneer in the global digital therapeutics (“DTx”) industry with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The report reads, “We initiate coverage on DRIO with a BUY rating and $25 PT based on a 5.6x EV/Sales multiple applied to FY:21E sales of $11.4mm, a discount to the est. peer average of 8.1x. We believe this multiple is warranted thanks to the growth prospects and quality of the product offering, underpinned by published efficacy…

Continue Reading

MondayAug 17, 2020 10:49 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Engages LaunchWorks for Commercial Release of MiQLab(TM)

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has engaged LaunchWorks to support the commercial launch of MiQLab(TM) prior to the end of September 2020. “We are making great progress in adding sales and manufacturing to LexaGene’s capabilities. I’m very pleased to announce our partnership with LaunchWorks, which will be responsible for manufacturing the consumables required to operate MiQLab,” Dr. Jack Regan, LexaGene’s CEO and Founder, stated in the news release. “Launchworks can currently manufacture enough products to easily support our commercial launch and have the…

Continue Reading

FridayAug 14, 2020 11:12 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. "This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare…

Continue Reading

WednesdayAug 12, 2020 12:07 pm

BioMedNewsBreaks – FWD Pharma 2020 to Shine Spotlight on Impactful Digital Trends in Today’s Shifting Landscape

Lincoln Health Network’s second annual FWD Pharma Conference is set to draw an engaging lineup of marketing and brand practitioners from leading organizations and shine the spotlight on biotech and life-science strategies in a complex digital world. Slated to be held Aug. 31-Sept. 1, 2020, the event promises to amplify attendees’ digital transformation of commercial operations and market access through omnichannel engagements, campaign analytics and marketing automation. FWD Pharma 2020 will feature keynotes, interactive panels, case studies, hands-on workshops, and peer-to-peer learning opportunities. A diverse group of marketing and brand practitioners from leading life-sciences organizations will share successful strategies to…

Continue Reading

WednesdayAug 12, 2020 10:27 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Q2 Revenue, Overview of Key Company Highlights and Development

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released a business update, including financial numbers and corporate achievements for the second quarter ended June 30, 2020. Highlights of the report include the company’s announcement of two Remote Patient Monitoring (“RPM”) agreements in the United States as well as an agreement with Williams Medical, which allowed Dario to enter the United Kingdom. In addition, the company reported Q2 revenues of $1.79 million, a 7.2% sequential increase from Q1 2020. "The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (B2B2C) digital therapeutics leader," said Dario CEO Erez…

Continue Reading